Venture&Growth
Location
Munich, Germany
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
CatalYm is a clinical-stage immuno-oncology company improving the outcomes of existing checkpoint inhibitor therapies in difficult-to-treat cancer types. The company has identified GDF-15 as a key cancer therapy resistance mechanism and is developing it as a safe and efficacious immune therapy for solid tumors. GDF-15, an immunosuppressant important for feto-maternal tolerance, is hijacked by cancer cells to evade an immune system attack. Visugromab, CatalYm’s lead antibody, has demonstrated durable anti-tumor efficacy with long-lasting objective responses in relapsed and refractory metastatic solid tumor patients in combination with anti-PD-1 treatment.
More CatalYm news
Amphista Therapeutics
Amphista Therapeutics is a UK-based biopharmaceutical company creating first-in-class therapeutics that harness the body’s natural...
Fire1
Irish MedTech company focused on remote monitoring of heart failure patients.
Spire Health
US-based Healthtech company providing remote patient monitoring solutions for COPD patients.